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Abstract
Background: OSCC is one of the most common malignancies and numerous clinical agents currently applied in combinative
chemotherapy. Here we reported a novel therapeutic strategy, SAHA and DDP-loaded PECE (SAHA-DDP/PECE), can improve
the therapeutic effects of intratumorally chemotherapy on OSCC cell xenografts.
Objective/Purpose: The objective of this study was to evaluate the therapeutic efficacy of the SAHA-DDP/PECE in situ
controlled drug delivery system on OSCC cell xenografts.
Methods: A biodegradable and thermosensitive hydrogel was successfully developed to load SAHA and DDP. Tumor-
beared mice were intratumorally administered with SAHA-DDP/PECE at 50 mg/kg (SAHA) +2 mg/kg (DDP) in 100 ul PECE
hydrogel every two weeks, SAHA-DDP at 50 mg/kg(SAHA) +2 mg/kg(DDP) in NS, 2 mg/kg DDP solution, 50 mg/kg SAHA
solution, equal volume of PECE hydrogel, or equal volume of NS on the same schedule, respectively. The antineoplastic
actions of SAHA and DDP alone and in combination were evaluated using the determination of tumor volume,
immunohistochemistry, western blot, and TUNEL analysis.
Results: The hydrogel system was a free-flowing sol at 10uC, become gel at body temperature, and could sustain more than
14 days in situ. SAHA-DDP/PECE was subsequently injected into tumor OSCC tumor-beared mice. The results demonstrated
that such a strategy as this allows the carrier system to show a sustained release of SAHA and DDP in vivo, and could
improved therapeutic effects compared with a simple additive therapeutic effect of SAHA and DDP on mouse model.
Conclusions: Our research indicated that the novel SAHA-DDP/PECE system based on biodegradable PECE copolymer
enhanced the therapeutic effects and could diminished the side effects of SAHA/DDP. The present work might be of great
importance to the further exploration of the potential application of SAHA/DDP-hydrogel controlled drug release system in
the treatment of OSCC.
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Introduction
Oral squamous cell carcinoma (OSCC) is one of the most
common malignancies leading to death that accounts for more
than 90% of all oral cancers [1]. Although the aetiological risk
factors are well documented and advances in diagnosis and
therapy have been made in the different treatment modalities, the
morbidity of OSCC have not improved significantly over the last
decades [2,3].
Histone deacetylase (HDAC) inhibitors have been shown to
acetylate the nucleosomal histones of condensed chromatin, and
cause the reactivation of genes silenced by hyperacetylated
histones [4]. HDAC inhibitors, including suberoylanilide hydro-
xamic acid (SAHA), have demonstrated therapeutic benefit as
monotherapy on a variety of hematological and solid tumor
cancer such as glioma, head and neck cancer, hematologic
malignancies and nonsmall-cell lung cancer (NSCLC) [5,6,7,8].
Cisplatin (DDP) is another strong and widely used chemotherapy
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1drug which is used to treat cancers including: sarcoma, small cell
lung cancer, germ cell tumors, lymphoma, and ovarian cancer
[9–14]. Though SAHA and DDP have been proven to be
effective therapeutic efficacy, they are also can cause serious side
effects. The conventional methods for delivering chemothera-
peutic agents fail to achieve therapeutic concentrations of drugs,
despite reaching toxic systemic levels. Moreover, the improve-
ment of the curative is accompanied by the resistance to the
drugs [15–18]. So, the novel controlled drug delivery systems are
necessary designed to deliver drugs at predetermined rates for
predefined periods at the target organ and overcome the
shortcomings of conventional drug formulations, therefore could
diminish the side effects and improve the life quality of the
patients. Thus, a suitable controlled drug delivery system is
extremely important for chemotherapy.
In our previous study, we prepared a new kind of biodegrad-
able, temperature sensitive and injectable poly (ethylene glycol)-
poly(e-caprolactone)-poly(ethylene glycol) (PEG-PCL-PEG,
PECE) hydrogel based on PEG and PCL which are biocompatible
and have been used in several FDA approved products [19]. The
PECE hydrogel was a flowing sol at low temperature and formed
a non-flowing gel at body temperature, the sol-gel-sol transition
behavior of it has been reported in our previously study. And the
results indicated that PECE hydrogen displayed a temperature-
dependent sol-gel-sol transition in normal saline. When the
concentration was above corresponding critical gelatin concentra-
tion, the aqueous solutions of PECE copolymer undergo a sol-gel-
sol transition as the temperature increases [20,21]. PECE also was
proved to be biocompatible, bioabsorbable and thermosensitive.
The thermosensitive hydrogel system had been successfully used
for honokiol, 5-Fu, and bFGF controlled delivery in cancer
treatment and the results presented its great sustained drug release
properties [22–25]. Based on the above results, the PECE
hydrogel might have great potential applications as an injectable
controlled drug delivery system.
In this report, we investigated the combined effects of HDAC
inhibitors SAHA and DDP in an oral squamous cell carcinoma
tumor model using the PECE hydrogels for controlled drug
delivery. Our results suggested that the SAHA combine DDP
delivered by PECE hydrogel have a significant therapeutic efficacy
in murine model. This strategy had potential application in
chemotherapy for the oral squamous cell carcinoma.
Materials and Methods
Animals and Cells
Female athymic nude mice (4–6 weeks) were obtained from the
Shanghai SLAC laboratory animal co. ltd (Shanghai, China). All
animals were handled in strict accordance with good animal
practice as defined by the relevant national and/or local animal
welfare bodies, and in accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. Animal experiments were approved
by the Institutional Animal Care and Treatment Committee of
Sichuan University (Chengdu, China).
Oral squamous cell carcinoma cells HSC-3 cells were main-
tained in Dulbecco’s modied Eagle’s medium (DMEM; Gibco,
USA) containing 10% fetal calf serum (Gibco, USA), penicillin
(100 U/L) and streptomycin (10 mg/L). HOK16E6E7 cells,
a human immortalized oral keratinocyte cell line, was cultured
in keratinocyte growth medium (KGM) containing 0.15 mM of
calcium, supplemented with EGF (Gibco, USA), both at 37uCi n
an atmosphere containing 5% CO2.
Reagents
SAHA was purchased from (Alexis Corp., San Diego, CA,
USA), and was dissolved in DMSO as stock solution. The
maximum volume (%) of DMSO in the experiment was less than
0.1%. DDP was purchased from Jintai Pharmaceutical Co. Ltd.
(Liaoling, PR China) and dissolved in PBS. Poly (ethylene glycol)
methyl ether (MPEG, Mn = 550), e-caprolactone (e-CL),
hexamethylene diisocyanate (HMDI), and stannous octoate
(Sn(Oct)2) were purchased from Sigma-Aldrich Chemical Co.
(USA).
Synthesis of PECE Hydrogel
PECE copolymer were synthesized and purified as reported
previously [19]. Briefly, PEG-PCL diblock copolymers were
prepared by ring opening polymerization of e-CL initiated by
MPEG using stannous octoate as catalyst; PEG-PCL-PEG triblock
copolymers were synthesized by coupling PEG-PCL diblock
copolymers using HMDI as coupling agent. The obtained PECE
copolymer was dissolved in AR grade dichloromethane and
reprecipitated from filtrate using AR grade petroleum ether. Then
the mixture was filtered and vacuum dried to constant weight at
room temperature. The obtained PECE copolymers were
characterized by FTIR (NICOLET 200SXV, Nicolet, USA),
1H-NMR (Varian 400 spectrometer, Varian, USA), and GPC
(Agilent 110 HPLC, USA).
Preparation of Injectable Thermosensitive Composite
Hydrogel
The drugs loaded injectable thermosensitive hydrogel was
prepared similar to the protocol reported previously [26,27].
First, PECE copolymer was well dissolved in water at certain
temperature and cooled to 4uC to form sol. Then, SAHA and
DDP solutions were mixed into the PECE sol to form
homogeneous solution, and the concentration of PECE was kept
at 30 wt%. The prepared drugs loaded hydrogel was inhaled into
injector and injected into or around the focus of infection in
animal. Thus, composite sol turned into gel state and acted as
depots for sustained release of drugs in situ when the cold sol is
warmed to body temperature (37uC) in vivo. At last, for the
degradation of the composite hydrogel, the introduced DDS was
gradually emanated from body.
Cytotoxicity Assay of PECE Copolymer
Cytotoxicity of PECE triblock copolymer to HOK16E6E7 and
HSC-3cells was evaluated by 3-[4, 5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide (MTT) assay. Cells were seeded on
96-well plates at a density of 10
4 cells/well in their usual culture
media. After 24 h, different amounts of PECE copolymer were
added 0 mg, 10 mg, 20 mg, 50 mg, 100 mg, 150 mg, 200 mg,
300 mg, or 400 mg each well, respectively. The normal saline
was used as the control groups. Cytotoxicity studies were
performed using MTT assay after 24 h, 48 h or 72 h. The
absorbance of the samples was measured at 570 nm. The cell
cytotoxicity of PECE copolymer is defined as the relative viability,
which is the ratio of the number of live cells to that of the control
cells (100%).
Murine Tumor Models and Treatment
The female nude mice were inoculated subcutaneously into the
right flank regions with 2610
6 HSC-3 cells/mouse resuspended in
0.1 ml of DMEM medium without serum and antibiotics. When
tumors were palpable one week later, the mice were randomly
assigned to six independent treatment groups (6 mice per group):
Anti-Tumor Effect of Controlled Drug Delivery
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with 100 ml blank hydrogel, (c) mice treated with 100 ml SAHA,
(d) mice treated with 100 ml DDP, (e) mice treated with 100 ml
combine SAHA with DDP (SAHA-DDP), (f) mice treated with
100 ml SAHA and DDP in thermosensitive hydrogel (SAHA-
DDP/PECE). SAHA and DDP were peritumorally administered
two times at the first dose and 14 days later. Tumor diameters
were measured every 3 days, and tumor volume was calculated
using the formula: Tumor size = (length) 6(width)
2 60.52. All
the animals were observed after administration, including the
general conditions (the activity, energy, hair, feces, behavior
pattern, and other clinical signs), body weight, and mortality. Mice
were sacrificed 14 days after the last treatment. Tumors were
excised and weighted, half of which were snap frozen immediately
for western blot assay, and anthers were fixed in 4% formalde-
hyde.
Toxicity Assessment
Possible side effects were observed through weight, appetite,
diarrhea, life span, and behavior until they were sacrificed. Organs
such as heart, liver, spleen, lung, and kidney were collected, fixed
in 4% paraformaldehyde solution and made into 4 mm sections
which were stained with hematoxylin and eosin (H&E) and
observed by two pathologists in a blinded manner under
a microscope.
Immunohistochemistry and TUNEL Assay
Mouse anti-human PCNA antibody (1:500, BD, USA) was
applied for detecting the tumor cell proliferation on the paraffin
section. Microvessel of tumor tissues was detected by Anti-CD34
antibody (1:500, BD, USA) on lung frozen tissue section.
TUNEL detection Analysis of apoptotic cells in tumor tissue
was measured by the TUNEL Apoptosis Detection Kit (Upstate
LabChem Inc, USA) following the manufacturer’s directions.
Three equal-sized fields (at 6400 magnification) were randomly
chosen and the mean number of green fluorescence-positive cells
was counted.
Western Blot Analysis
To prepare lysates from dissected in vivo tumors, samples
were snap frozen in liquid nitrogen immediately after animal
sacrifice and stored at –80uC before use. The lysates were
incubated on ice in RIPA lyses buffer for 30 min before being
homogenized by a mortar and pestle. Apoptosis related proteins
were detected by anti-Caspase-3 antibody, anti-Caspase-8
antibody, anti-Caspase-9 antibody (Cell Signaling, USA). Iso-
lation of histones was performed as described previously [28].
Total and acetyl-Histone H3 were detected by Anti-Histone H3
polyclonal antibody and Anti-acetyl-Histone H3 polyclonal
antibody respectively. The primary antibody was detected with
HRP-conjugated anti-mouse secondary antibody and developed
with an enhanced chemiluminescence detection kit (Pierce,
USA). Equal protein loading was confirmed by detection of
GAPDH (R&D, USA).
Statistical Analysis
Data are expressed as the mean 6 SD. Statistical analysis
was performed by Student’s t test for comparing two groups
and by ANOVA for multiple group comparisons. p values less
than 0.05 were considered to be statistically significant. All
statistical tests were two-sided. SPSS 16.0 was used for all
statistical analyses.
Results
Synthesis and Characterization of PECE Copolymers
The PECE triblock copolymer was synthesized according to
Fig.1. FTIR,
1H-NMR and GPC were used to characterize the
chemical structure of the PECE copolymer (data not shown) [19].
The Mn and PEG/PCL block ratio of PECE triblock copolymer
calculated from
1H-NMR spectra was 3630 and 1100/2530
respectively.
Cytotoxicity Assay of PECE Copolymer
Firstly, We wanted to verify whether the prepared PECE
copolymer has cytotoxicity to the human oral normal and cancer
cell line, so HOK16E6E7 (an immortalized human oral
keratinocyte cell line) and HSC-3 ( a human tongue squamous
cell carcinoma cell line) were chose in the cytotoxicity assay of
PECE copolymers. Fig. 2 exhibits the HOK16E6E7 and HSC-3
cells viability at the presence of PECE copolymer at different
concentrations. The cell viability decreased with increase of PECE
copolymer amount. But the HOK16E6E7 and HSC-3 cells
viability was yet higher than 82% and 65%, respectively, even
when the input PECE copolymers were 400 mg per well.
According to Fig. 2, the HSC-3 cell viability of PECE copolymer
was higher compared to HOK16E6E7 group. Thus, the PECE
copolymers prepared in this paper could be regarded as
a biocompatible with low cell cytotoxicity controlled drug delivery
systems.
Antitumor Activity of SAHA-DDP/PECE In Vivo
In the mice model of oral squamous cell carcinoma xenografts,
the female nude mice received 2 6 10
6 HSC-3 cells via
subcutaneously into the right flank regions. Mice were assigned
to six groups, receiving NS, PECE, SAHA, DDP, SAHA-DDP
and SAHA-DDP/PECE, respectively.
Two combination-therapy groups, especially the group treated
with SAHA-DDP/PECE were significantly reduced the growth of
tumors compared with other control groups. The growth delay of
tumors in mice injected with SAHA-DDP/PECE continued until
the day of sacrifice, reaching a mean volume of 62.43 mm
3, while
tumors of mice injected with NS, PECE, SAHA, DDP and SAHA-
DDP grew persistently, resulting in mean volumes of 148.60 mm
3,
187.60 mm
3, 249.71 mm
3, 279.41 mm
3 and 284.32 mm
3 (Fig. 3B
and C, p , 0.05). Consistent with the data of tumor volume, the
mean weight of tumors of mice treated with SAHA-DDP/PECE
was 0.04 6 0.01 g, accounting for 22.18% of that of mice treated
with NS (0.21 6 0.10 g), 22.42% of mice treated with PECE (0.20
6 0.04 g), 25.22% of mice treated with SAHA (0.18 6 0.04 g),
33.54% of mice treated with DDP (0.14 6 0.02 g) and 43.98% of
mice treated with SAHA-DDP (0.10 6 0.01 g).
To provide evidence that the drugs were detectable at the tumor
site and the duration of drug presence following drug delivery, we
Figure 1. Synthesis of PECE copolymers.
doi:10.1371/journal.pone.0033860.g001
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reflect the controlled releases ability of SAHA-DDP/PECE
indirectly. As shown Fig. 3C, the level of acetyl-Histone H3 was
observably reduced with the lapse of time in SAHA-DDP group
while high expression level of acetyl-Histone H3 was maintained
in the SAHA-DDP/PECE group in an extended period.
Systematic Toxicity in the SAHA-DDP/PECE Treated Mice
Since earlier researches confirmed the severe irreversible side
effects of DDP and SAHA treatment, we compared the body
weight and other side effects on mice treated with free SAHA,
DDP or SAHA-DDP/PECE. No difference of body weight was
observed among the SAHA-DDP/PECE group compared with
the other groups at the end of the study (Fig. 4A). After mice were
sacrificed, their liver, lung, kidney, spleen and heart were
harvested and H&E histological staining was performed. As
observed by two pathologists in a blinded manner, we found that
mice treated with SAHA-DDP/PECE showed no slight changes of
toxicity to the organ tissues, compared with the normal organ
tissues from mice receiving NS (Fig. 4B). In addition, no
conspicuous adverse effects in gross measures were observed, such
as appetite, feeding, ruffling of fur, behavior change, etc.
SAHA-DDP/PECE Inhibited Cell Proliferation and
Intratumoral Angiogenesis In Vivo
To address possible mechanisms responsible for the in vivo
antitumor activity of combination-therapy groups, we made an
inquiry into phenotypic changes of tumor tissues in cell pro-
liferation and intratumoral angiogenesis. We first performed
PCNA staining to assess the effect of combination-therapy groups,
suppression on tumor cell proliferation. Tumor tissues of two
combination-therapy groups, especially the group treated with
SAHA-DDP/PECE were exhibit much less staining for PCNA
compared with that in tumor tissues of mice treated with NS,
PECE, SAHA, DDP (Fig. 5A, p , 0.05). Some studies have shown
that MVD and perimeter are significantly different between
normal mucosa and OSCC [29–31]. Therefore, MVD was
evaluated in the tumors harvested from mice. We examined the
tumor tissues with anti-CD34 and the most highly vascularized
area of each tumor was identified and five high-powered fields
were counted in this area for MVD. As shown in Fig. 5B, the most
significant reduction of MVD was observed in the group treated
with SAHA-DDP/PECE (19.764.8) compared with the other
groups. Thus, it may be hypothesized that the anti-tumor effects of
SAHA-DDP/PECE could be contributed to its ability of inhibits
cell proliferation and intratumoral angiogenesis. However, no
significant difference was found among SAHA, DDP group and
SAHA-DDP group.
SAHA-DDP/PECE Induced Apoptosis In Vivo
The cytotoxic effects mediated by combination-therapy groups
were also analyzed to evaluate whether the cytotoxic mechanisms
of the constructs observed included the element of apoptosis in the
HSC-3 tumor model. We performed the in situ TUNEL assay to
evaluate the influence of combination-therapy groups on apoptosis
in tumor cells. We observed an apparently elevated apoptosis rate
in tumors of mice with combination-therapy, especially the group
treated with SAHA-DDP/PECE compared with that in tumors of
mice injected with NS, PECE, SAHA, DDP and (Fig. 6A, p ,
0.05). Therefore, SAHA-DDP, especially SAHA-DDP/PECE
could led to reduced cell proliferation and increased apoptosis in
vivo, which associated with inhibition of tumor growth.
To further determine the apoptotic mechanism in the protein
level in vivo, western blot assay was performed. The result showed
that the protein level of p53, cleaved Caspase-8, cleaved caspase-9
and cleaved caspase-3 in the tumor tissue of the SAHA-DDP/
PECE treated mice much higher than the other groups (Fig. 6B).
These data indicated that the observed cytotoxic effects of SAHA-
DDP/PECE on HSC-3 tumor xenografts in nude mice also
seemed to be mediated by the efficient induction of apoptotic
mechanism just like our results in vitro [32].
Discussion
In this study, we provided a novel chemotherapy protocol for
oral squamous cell carcinoma. The PECE thermosensitive
hydrogel have showed promising application as a chemotherapeu-
tics controlled drug delivery [24]. We combined SAHA with DDP
and utilized the SAHA-DDP/PECE complexes to induce an
antitumor activity against the oral squamous cell carcinoma
xenografts in a therapeutic setting. We found that the PECE
hydrogel could be a novel delivery system and PECE hydrogel
delivering DDP and SAHA had promising application in cancer
chemotherapy.
DDP has a powerful therapeutic effect against oral carcinoma,
but the resistance of tumor cells to DDP and dose-related toxicity
remain two of the most important problems in the chemotherapy
of clinical OSCC [32]. When the DDP dose was too high, the side-
toxic effect was enhanced; when the DDP dose was low, the
anticancer effect was too low. Researchers have been seeking
a combinative treatment regimen to improve the effect of
chemotherapy, so combination therapy using two or more
chemotherapeutic agents was one of the most common strategies
used in current oncology. SAHA was a newly developed HDAC
inhibitor which could alter gene transcription and expression
profile involved in cell-cycle regulation, tumor suppression,
Figure 2. Cytotoxicity Assay of PECE Copolymer. Different
amounts of PECE copolymer were added from 5 to 400 mg each well,
and after 24, 48 and 72 hours, survival rate of HOK16E6E7 and HSC-3
cells was determined by MTT assay. Data were obtained from three
independent triplicate experiments and were presented as mean 6 S.D
(*P,0.01).
doi:10.1371/journal.pone.0033860.g002
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tumor suppressor genes, as well as other genes that are responsible
for cell cycle progression, cell proliferation, programmed cell
death, and differentiation. Thus, blocking histone deacetylation
may allow the body to block this tumor growth and prevent
progression.
We have reported that low concentrations of SAHA synergized
with DDP in combination therapy to induce a level of cytotoxicity
and apoptosis in both Tca8113 and KB cell lines greater than that
mediated by either agent alone, or that predicted by an additive
model [32]. Previously, some researchers also have reported that
the combination of SAHA with DDP possessed synergistic
cytotoxicity against the other human cancer cells [34–38]. SAHA
mediated the cleavage and activation of the pro-apoptotic Bcl-2
family member Bid. Furthermore, diverse apoptosis-associated
proteins, including p53, cytochrome C and caspase-3 were
involved in the induction of apoptosis. Their results suggest that
concurrent treatment with SAHA enhances tumor cell sensitivity
to subtoxic doses of DDP. Though this may be regarded as a novel
strategy for treatment of cancer, it has not been detected in vivo.
Nevertheless, further studies including generating OSCC xeno-
graft mouse model should be conducted to confirm the in vitro
results.
To design a better combinative chemotherapeutic regimen in
vivo,thereshouldbe abetter focusoncellkilling andlowersystemic
toxicity. The selection of vectors always played an important role in
the succession of chemotherapy protocol. And strategies such as
sustained and localized therapy may have the potential to improve
the efficacy of medical treatment. A kind of biodegradable and
injectablepoly(ethyleneglycol)-poly(‘‘-caprolactone)-poly(ethylene
glycol) (PEG-PCL-PEG, PECE) triblock copolymer, can be used as
a delivery vector to load chemotherapeutic drugs for intratumoral
infusion chemotherapy. PECE hydrogel we have prepared in this
study would be an ideal controlled drug delivery system for SAHA
and DDP. As our previously study, a hydrogel solution (30 wt%,
0.5 mL)wassubcutaneouslyinjectedintoKunMingmice.Afterday
1,day3,day7,andday14followingsubcutaneousinjection,andthe
opaquegelmaintaineditsintegrityintheperiodofobservation.The
size of gel decreased during degradation, and at day 14, the gel
almostdisappeared.Therefore,PECEhydrogelwehavepreparedin
this study could sustain more than 14 days in situ [39,40]. It was
a free-flowing sol at room temperature or below critical gelation
temperaturebecamegelatbodytemperature.Thissol-geltransition
behavior of PECE hydrogel gives the advantage of simply mixing it
with pharmaceutical agents at low temperature in which it then
becomes an in situ gel-forming controlled drug delivery system in
Figure 3. Antitumor activity of SAHA-DDP/PECE in vivo. In the mice model of oral squamous cell carcinoma xenografts, the female nude mice
received 2 610
6 HSC-3 cells via subcutaneously into the right flank regions. (A) The mice were then treated with NS, PECE, SAHA, DDP, SAHA-DDP
and SAHA-DDP/PECE every two weeks for a total of two doses starting on day 7 (n=6 mice per group). Tumor volumes of mice from different groups
of HSC-3 tumor model. (B) Representative tumors of OSCC mice model from NS, PECE, SAHA, DDP and SAHA-DDP control group and SAHA-DDP/PECE
treated mice. Data are representative of at least two separate experiments. Bars, means 6 SD (*P,0.05).(C) When tumors were palpable, the mice
were randomly assigned to two independent treatment groups( n=12 mice per group): mice treated with 100 ml combine SAHA with DDP (SAHA-
DDP), or treated with 100 ml SAHA and DDP in thermosensitive hydrogel (SAHA-DDP/PECE). At the date of 1, 3, 7, 14 and 21 three mice were
sacrificed separately. The ribonucleoprotein of the tumor tissues was extracted and the expression of acetyl-Histone H3 and Histone H3 was detected
by western blot.
doi:10.1371/journal.pone.0033860.g003
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strongly support that PECE hydrogel can endue the delayedrelease
properties and increased permeability of drugs. For intratumoral
chemotherapy, prolonged stay and increased permeability of drugs
are helpful for better disease control. In fact, the SAHA-DDP/
PECE hydrogel system did show significantly increased therapeutic
effects for OSCC. SAHA-DDP/PECE hydrogel system with direct
intratumoralinjectionsmaybeausefulmethodintreatmentfororal
cancer and other solid tumors.
Figure 4. Systematic toxicity in the SAHA-DDP/PECE treated mice. H&E staining of section of major tissues obtained from tumor beard mice
which received two doses of NS, PECE, SAHA, DDP, SAHA-DDP and SAHA-DDP/PECE. Heart, liver, spleen, lung and kidney were harvested at day 28
after intravenous injection. (A) Mean body weights on days 7, 10, 13, 16, 19, 22, 25 and 28 of mice treated with two doses of NS, PECE, SAHA, DDP,
SAHA-DDP and SAHA-DDP/PECE; error bars correspond to 95% confidence intervals, Values are means6SD (n = 10 mice per group).
doi:10.1371/journal.pone.0033860.g004
Figure 5. SAHA-DDP/PECE inhibited cell proliferation and intratumoral angiogenesis in vivo. (A) PCNA-positive cells were rich in NS and
PECE groups. Whereas, the percentage of PCNA-positive cells in SAHA, DDP, SAHA-DDP and SAHA-DDP/PECE groups were significantly decreased in
turn (*P,0.05). (magnification,6200) (B) Angiogenesis within tumors was detected by CD34 staining of micro vessels. The average number of micro
vessels per vascular hot spot was significantly decreased in SAHA-DDP/PECE treated tissues compared with those in the three control groups
(*P,0.05).
doi:10.1371/journal.pone.0033860.g005
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delivery system for the treatment of experimental OSCC by
administrating the DDP and SAHA loaded PECE hydrogel
peritumorally of OSCC-bearing mice. Our experimental results
demonstrated that such a strategy as this allows the carrier system
to show a sustained release of DDP and SAHA in vivo as well as
improved therapeutic effects compared with a simple additive
therapeutic effect of SAHA-DDP on murine OSCC. Furthermore,
peritumorally administration of the SAHA-DDP/PECE was well
tolerated and showed with no observable toxicity.
In conclusion, our data showed that intratumoral delivery of
SAHA-DDP/PECE system was an efficient way to transfer
Figure 6. SAHA-DDP/PECE induced apoptosis in vivo. (A) Induction of apoptosis was indicated by TUNEL assay. The TUNEL-positive cells
display dark green nuclei and are observed under a fluorescence microgroup (6400 magnification). TUNEL-positive nuclei were significantly increased
in SAHA-DDP/PECE treated tissues compared with those in the control groups (*P,0.05). (B) Detection of caspase-3, Caspase-8 and Caspase-9 by
Western blots. GAPDH was used as equal loading control.
doi:10.1371/journal.pone.0033860.g006
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e33860chemical drugs to the tumor. And the administration of SAHA-
DDP/PECE complexes led to the significant inhibition tumor
grows of OSCC with no conspicuous systemic toxicity. So the
treating oral squamous cell carcinoma by the PECE hydrogel
delivered DDP and SAHA may be a new and interesting cancer
chemotherapy protocol. SAHA-DDP/PECE hydrogel system with
direct intratumoral injections may be a useful method in treatment
for oral cancer and other solid tumors.
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